🚀 VC round data is live in beta, check it out!
Prime Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Prime Medicine and similar public comparables like Blue Jet Healthcare, Jade Biosciences, Kura Oncology, Tempo Scan Pacific and more.
Prime Medicine Overview
About Prime Medicine
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Founded
2019
HQ
Employees
214
Website
Financials (LTM)
EV
$649M
Prime Medicine Financials
Prime Medicine reported last 12-month revenue of $8M and negative EBITDA of ($196M).
In the same LTM period, Prime Medicine generated $8M in gross profit, ($196M) in EBITDA losses, and had net loss of ($193M).
Revenue (LTM)
Prime Medicine P&L
In the most recent fiscal year, Prime Medicine reported revenue of $5M and EBITDA of ($201M).
Prime Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | $8M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($196M) | XXX | ($201M) | XXX | XXX | XXX |
| EBITDA Margin | (2329%) | XXX | (4340%) | XXX | XXX | XXX |
| EBIT Margin | (2296%) | XXX | (4338%) | XXX | XXX | XXX |
| Net Profit | ($193M) | XXX | ($201M) | XXX | XXX | XXX |
| Net Margin | (2290%) | XXX | (4342%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Prime Medicine Stock Performance
Prime Medicine has current market cap of $744M, and enterprise value of $649M.
Market Cap Evolution
Prime Medicine's stock price is $4.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $649M | $744M | 0.0% | XXX | XXX | XXX | $-1.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPrime Medicine Valuation Multiples
Prime Medicine trades at 76.9x EV/Revenue multiple, and (3.3x) EV/EBITDA.
EV / Revenue (LTM)
Prime Medicine Financial Valuation Multiples
As of March 21, 2026, Prime Medicine has market cap of $744M and EV of $649M.
Equity research analysts estimate Prime Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prime Medicine has a P/E ratio of (3.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $744M | XXX | $744M | XXX | XXX | XXX |
| EV (current) | $649M | XXX | $649M | XXX | XXX | XXX |
| EV/Revenue | 76.9x | XXX | 140.0x | XXX | XXX | XXX |
| EV/EBITDA | (3.3x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/EBIT | (3.4x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 76.9x | XXX | — | XXX | XXX | XXX |
| P/E | (3.9x) | XXX | (3.7x) | XXX | XXX | XXX |
| EV/FCF | (4.0x) | XXX | (3.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Prime Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Prime Medicine Margins & Growth Rates
Prime Medicine's revenue in the last 12 month grew by 202%.
Prime Medicine's revenue per employee in the last FY averaged $0.0M.
Prime Medicine's rule of 40 is (2127%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prime Medicine's rule of X is (1823%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Prime Medicine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 202% | XXX | 379% | XXX | XXX | XXX |
| EBITDA Margin | (2329%) | XXX | (4340%) | XXX | XXX | XXX |
| EBITDA Growth | (14%) | XXX | (17%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (2127%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (1823%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1130% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1848% | XXX | 3468% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 4598% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Prime Medicine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Blue Jet Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Jade Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Kura Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| Annexon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prime Medicine M&A Activity
Prime Medicine acquired XXX companies to date.
Last acquisition by Prime Medicine was on XXXXXXXX, XXXXX. Prime Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Prime Medicine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPrime Medicine Investment Activity
Prime Medicine invested in XXX companies to date.
Prime Medicine made its latest investment on XXXXXXXX, XXXXX. Prime Medicine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Prime Medicine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Prime Medicine
| When was Prime Medicine founded? | Prime Medicine was founded in 2019. |
| Where is Prime Medicine headquartered? | Prime Medicine is headquartered in United States. |
| How many employees does Prime Medicine have? | As of today, Prime Medicine has over 214 employees. |
| Who is the CEO of Prime Medicine? | Prime Medicine's CEO is Allan Reine. |
| Is Prime Medicine publicly listed? | Yes, Prime Medicine is a public company listed on Nasdaq. |
| What is the stock symbol of Prime Medicine? | Prime Medicine trades under PRME ticker. |
| When did Prime Medicine go public? | Prime Medicine went public in 2022. |
| Who are competitors of Prime Medicine? | Prime Medicine main competitors are Blue Jet Healthcare, Jade Biosciences, Kura Oncology, Tempo Scan Pacific. |
| What is the current market cap of Prime Medicine? | Prime Medicine's current market cap is $744M. |
| What is the current revenue of Prime Medicine? | Prime Medicine's last 12 months revenue is $8M. |
| What is the current revenue growth of Prime Medicine? | Prime Medicine revenue growth (NTM/LTM) is 202%. |
| What is the current EV/Revenue multiple of Prime Medicine? | Current revenue multiple of Prime Medicine is 76.9x. |
| Is Prime Medicine profitable? | No, Prime Medicine is not profitable. |
| What is the current EBITDA of Prime Medicine? | Prime Medicine has negative EBITDA and is not profitable. |
| What is Prime Medicine's EBITDA margin? | Prime Medicine's last 12 months EBITDA margin is (2329%). |
| What is the current EV/EBITDA multiple of Prime Medicine? | Current EBITDA multiple of Prime Medicine is (3.3x). |
| What is the current FCF of Prime Medicine? | Prime Medicine's last 12 months FCF is ($163M). |
| What is Prime Medicine's FCF margin? | Prime Medicine's last 12 months FCF margin is (1935%). |
| What is the current EV/FCF multiple of Prime Medicine? | Current FCF multiple of Prime Medicine is (4.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.